Skip to content

Study · Non-randomized trial · n = 35 · 2013

2 results

HOXA10 protein expression in the endometrium of normally menstruating women after receiving GnRH antagonist.

Sirayapiwat P, Triratanachat S, Tantbirojn P, Ruangvejvorachai P, Suwajanakorn S

European journal of obstetrics, gynecology, and reproductive biology28 Mar 2013Cited by 2 (Europe PMC)

PMID23541416 (opens in a new tab)DOI10.1016/j.ejogrb.2013.03.006 (opens in a new tab)PepBankPUB-23541416
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanNon-randomized trialMechanism

    In normally menstruating women, ganirelix cycles showed higher endometrial HOXA10 nuclear staining than natural cycles.

    In plain wordsIn normally menstruating women, ganirelix cycles showed more HOXA10 nuclear staining than natural cycles.

    Peptide
    Ganirelix
    Outcome
    IncreaseHOXA10 nuclear staining
    Study

    n = 35

    Comparator
    Natural control cycle
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg dailyAs given in this study (human).

    Source sentences

    Summary
    The percentage of HOXA10 nuclear staining in the endometrium collected from GnRH antagonist-treated cycles was higher than that of the natural cycles
    3 context sentences
    Summary · context
    Thirty-five volunteers were recruited into this prospective, self-controlled study, which was divided into two cycles, the first a natural control cycle and the second a GnRH antagonist-treated cycle.
    Summary · context
    In the GnRH antagonist-treated cycle, when the leading follicle was 15 mm, ganirelix (Orgalutran®) 0.25mg was administered daily.
    Summary · context
    Finally, endometrial biopsy was performed on day 6 after documented ovulation, which corresponds to the window of implantation.
  2. 02HumanNon-randomized trialMechanism

    In normally menstruating women, endometrial HOXA10 IHC scores did not differ between ganirelix and natural cycles.

    In plain wordsIn normally menstruating women, HOXA10 staining scores did not differ between ganirelix and natural cycles.

    Peptide
    Ganirelix
    Outcome
    Direction not reportedHOXA10 IHC score
    Study

    n = 35

    Comparator
    Natural control cycle
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg dailyAs given in this study (human).

    Source sentences

    Summary
    The percentage of HOXA10 nuclear staining in the endometrium collected from GnRH antagonist-treated cycles was higher than that of the natural cycles, whereas the IHC-scores showed no difference between the two cycles.
    3 context sentences
    Summary · context
    Thirty-five volunteers were recruited into this prospective, self-controlled study, which was divided into two cycles, the first a natural control cycle and the second a GnRH antagonist-treated cycle.
    Summary · context
    In the GnRH antagonist-treated cycle, when the leading follicle was 15 mm, ganirelix (Orgalutran®) 0.25mg was administered daily.
    Summary · context
    Finally, endometrial biopsy was performed on day 6 after documented ovulation, which corresponds to the window of implantation.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.